Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Metastatic Colorectal Cancer Care: From Clinical Evidence to Real-World Excellence : Episode 6
Translating Real-World Outcomes in mCRC Into Patient Conversations
Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line metastatic colorectal cancer therapies.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
Now Viewing
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
EP: 9.Defining Future Needs for Real-World Evidence in mCRC
EP: 10.Applying Third-Line Therapy in mCRC: Community vs Academic Settings
EP: 11.Improving Care for mCRC: Overcoming Barriers and Building Confidence in Community Practice
EP: 12.Enhancing Support and Care Coordination in mCRC
Panelists highlight how real-world outcomes shape patient discussions, especially when setting realistic expectations about efficacy, safety, and quality of life with third-line options.
They note that real-world evidence with trifluridine/tipiracil plus bevacizumab and with fruquintinib confirms trial findings, providing confidence to patients about likely benefits.
By framing treatment conversations around both clinical data and real-world outcomes, clinicians can foster shared decision-making that aligns patient goals with available therapies.
Related Videos
Related Content
